



Tufts Center for the Study of Drug Development

TUFTS UNIVERSITY

# Impact REPORT

ANALYSIS AND INSIGHT INTO CRITICAL DRUG DEVELOPMENT ISSUES

## Global regenerative medicine market is poised for strong growth

*Europe, Japan, U.S. are pursuing different product development pathways*

- Regenerative medicine (RM) therapies have high potential to address a broad range of unmet medical needs.
- The RM sector today in Europe, Japan and the U.S. includes more than 640 privately held and publicly traded companies.
- A strong RM product pipeline is paving the way for a global market that could reach \$68B by 2020.
- Cell therapy products account for 76% of the 915 RM products in development in Europe, Japan, and the U.S., with gene therapy products accounting for the balance.
- Despite divergent product development trajectories, Europe, Japan, and the U.S. share common challenges.